NCT07427888|Completed
Loading search results
Sponsor study identifier
Secondary identifiers
OTHER · Clinical Research Unit, Institute of Oncology Ljubljana
interventional
8
1 country
1
Study Start
October 1, 2022
Actual (reported)Primary Completion
October 31, 2023
Actual (reported)Study Completion
October 31, 2023
Actual (reported)This study evaluates the effectiveness and safety of an implantable intrathecal pump for the treatment of cancer-related pain compared with standard subcutaneous analgesic infusion. Cancer-related pain can be difficult to control with systemic opioid therapy and is often associated with significant side effects and reduced quality of life. Implantable intrathecal pumps allow direct delivery of analgesic medication into the intrathecal space, enabling effective pain control with lower drug doses and fewer systemic adverse effects. The study compares pain intensity, symptom burden, medication requirements, and quality of life in patients receiving analgesia via an implantable intrathecal pump versus those treated with a subcutaneous pump. The results of this study aim to support the introduction of implantable intrathecal pumps into routine clinical practice for selected patients with refractory cancer pain.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 31, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2022
Actual (reported)October 31, 2023
Actual (reported)October 31, 2023
Actual (reported)February 4, 2026
Actual (reported)February 23, 2026
Actual (reported)Change in Pain Intensity
Change in pain intensity assessed using a numerical rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain), including assessment of average and maximum pain.
Baseline and 4 weeks after initiation of analgesic therapy
Implantable intrathecal pump used for continuous intrathecal delivery of analgesic medication for cancer pain.
Subcutaneous infusion pump used for continuous analgesic medication delivery.
Subcutaneous infusion pump used for continuous delivery of analgesic medication in patients with cancer-related pain.
Implantable intrathecal pump surgically implanted for continuous delivery of analgesic medication into the intrathecal space for management of refractory cancer-related pain.
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
8 participants (actual enrollment reported by the registry).
First Submitted
February 4, 2026
First Posted
February 23, 2026
Study Start
October 1, 2022
Improving Cancer Pain Management Through Teach-Back Educational Approach for Patients and Primary Caregivers: A Pilot Study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
October 31, 2023
Actual (reported)Study Completion
October 31, 2023
Actual (reported)Last Updated
February 23, 2026
Record last verified: 2026-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: